Integrative Proteomics Inc.
This article was originally published in Start Up
Executive Summary
Starting with linear amino acid sequence information, researchers are faced with the task of completing dossiers for particular proteins, filling in gaps in knowledge about their structures, their biochemical functions, and their physiological functions, to gain knowledge about what diseases or processes they regulate. Pharmaceutical and biotech companies know that this will ultimately result in drugs that interact with proteins to provide therapeutic benefits. The founders of Integrative Proteomics Inc. mean for this to happen sooner, rather than later. They have amassed a platform of protein-focused skills aimed at informing the drug discovery process at every step of the way, from target selection to lead optimization, and even at the marketing end, where proteomics could lead to population-customized drugs. The founders of IPI term their mission "pharmaceutical proteomics."